Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus

NCT01585558 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Atrophy
Vaginal Diseases

Interventions

DRUG: Ospemifene (Dose 1)
DRUG: Ospemifene (Dose 2)
DRUG: Placebo

Sponsor

Shionogi

Collaborators

[object Object]